Germany and Serbia weaken Stada's six-month performance
This article was originally published in Scrip
Stada's domestic sales fell by 8% to €260 million in the first six months of this year, while those in Serbia, the company's seventh largest individual market, fell by 21% to €36 million. The decline was partially offset by the 24% growth of sales to €97 million in Russia, its second most important national market.
You may also be interested in...
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.